SecBot SecBot
8-K ·Filed Nov 3, 2026

FTH

Faeth Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed13d 13h ago SEC0001193125-26-444410
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the Phase 2 PIK-201 topline readout expected by year-end 2026. The Fast Track designation adds regulatory momentum but does not change the binary nature of the data. Monitor for trial results which will determine the stock's direction.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$19.65
T+0 close · Nov 3, 2026 · via day close
Latest settled
−34.25%
T+5 · $12.92 · next T+20 in 15d
Vs SPY
−33.66%
α at T+5
Latest observation
−48.34%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $19.65entry
  2. T+1 · 13d ago +1.73%α +0.08% · $19.99
  3. T+5 · 7d ago −34.25%α −33.66% · $12.92
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Faeth Therapeutics reported Q3 2026 net loss of $20.4M ($0.79/share) vs $4.6M ($3.62/share) in Q3 2025, driven by increased R&D and G&A costs post-merger. Cash and securities totaled $174.8M at quarter end. The FDA granted Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer, and topline Phase 2 PIK-201 data is expected by year-end.

Key Financial Metrics

EPS
−$0.79

Key Facts

  • Net loss of $20.4M for Q3 2026 vs $4.6M in Q3 2025
  • Cash, equivalents and marketable securities of $174.8M as of Sep 30, 2026
  • FDA granted Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
  • Topline Phase 2 PIK-201 data expected by year-end 2026
  • R&D expenses $11.7M in Q3 2026 vs $2.5M in Q3 2025
  • G&A expenses $10.4M in Q3 2026 vs $2.3M in Q3 2025
  • Weighted-average shares outstanding 25.8M vs 1.3M year ago

Financial Impact

Net loss widened to $20.4M from $4.6M; cash burn $11.6M sequentially from $186.4M to $174.8M

net losscash positionR&D spend

Risk Factors

  • Clinical trial failure risk for PIK-201 and PIK-101
  • Cash runway of $174.8M may require additional financing before profitability
  • No approved products or revenue stream
  • High volatility typical of clinical-stage biotech

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-444410
Document: d144290d8k.htm0001193125-26-444410
Document: 0001193125-26-444410-index-headers.html0001193125-26-444410
Document: 0001193125-26-444410-index.html0001193125-26-444410
Document: 0001193125-26-444410.txt0001193125-26-444410
8-K Data (Synthetic)0001193125-26-444410

Track record

12 reports on FTH

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +35.00% at T+60 after the Aug 11, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $10.03 Now $9.28 −7.48% settles Nov 17
  3. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
  4. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
  5. Nov 3, 202613d ago 8-K Neutral 5/10 Viewing Entry $19.65 to $19.99 Now $9.28 −52.77% ▲ +1.73% +0.08% vs SPY
  6. Oct 27, 202620d ago 3 Neutral 2/10 Entry $19.20 to $18.75 Now $9.28 −51.67% ▼ −2.34% −1.96% vs SPY
  7. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $19.11 to $19.20 Now $9.28 −51.44% ▲ +0.47% +0.13% vs SPY
  8. Sep 15, 20268w ago 3 Neutral 2/10 Entry $34.24 to $35.13 Now $9.28 −72.90% ▲ +2.60% +1.47% vs SPY
  9. Aug 11, 202613w ago 144 Bearish 5/10 Entry $30.00 to $29.38 Now $9.28 +69.07% ▲ +2.07% +2.32% vs SPY
  10. Aug 4, 202614w ago 8-K Neutral 3/10 Entry $25.50 to $24.59 Now $9.28 −63.61% ▼ −3.57% −3.37% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (11h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026